552 related articles for article (PubMed ID: 30125215)
1. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
Kurtz DM; Scherer F; Jin MC; Soo J; Craig AFM; Esfahani MS; Chabon JJ; Stehr H; Liu CL; Tibshirani R; Maeda LS; Gupta NK; Khodadoust MS; Advani RH; Levy R; Newman AM; Dührsen U; Hüttmann A; Meignan M; Casasnovas RO; Westin JR; Roschewski M; Wilson WH; Gaidano G; Rossi D; Diehn M; Alizadeh AA
J Clin Oncol; 2018 Oct; 36(28):2845-2853. PubMed ID: 30125215
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
[TBL] [Abstract][Full Text] [Related]
3. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
Alig S; Macaulay CW; Kurtz DM; Dührsen U; Hüttmann A; Schmitz C; Jin MC; Sworder BJ; Garofalo A; Shahrokh Esfahani M; Nabet BY; Soo J; Scherer F; Craig AFM; Casasnovas O; Westin JR; Gaidano G; Rossi D; Roschewski M; Wilson WH; Meignan M; Diehn M; Alizadeh AA
J Clin Oncol; 2021 Aug; 39(23):2605-2616. PubMed ID: 33909455
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
Wu FT; Lu L; Xu W; Li JY
Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
Frank MJ; Hossain NM; Bukhari A; Dean E; Spiegel JY; Claire GK; Kirsch I; Jacob AP; Mullins CD; Lee LW; Kong KA; Craig J; Mackall CL; Rapoport AP; Jain MD; Dahiya S; Locke FL; Miklos DB
J Clin Oncol; 2021 Sep; 39(27):3034-3043. PubMed ID: 34133196
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
Cherng HJ; Herrera A
Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
[TBL] [Abstract][Full Text] [Related]
7. Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA.
Melani C; Wilson WH; Roschewski M
Best Pract Res Clin Haematol; 2018 Sep; 31(3):285-292. PubMed ID: 30213398
[TBL] [Abstract][Full Text] [Related]
8. Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma.
Zhao K; Zheng X; Liu X; Liu T; Ke Z; Zhu F; Wen Q; Xin B; Li Q; Zhang L
Oncologist; 2024 May; 29(5):e672-e680. PubMed ID: 38297976
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma.
Bachet JB; Blons H; Hammel P; Hariry IE; Portales F; Mineur L; Metges JP; Mulot C; Bourreau C; Cain J; Cros J; Laurent-Puig P
Clin Cancer Res; 2020 Oct; 26(19):5208-5216. PubMed ID: 32605910
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of circulating tumor DNA in lymphoma: a meta-analysis.
Yao L; Xu H; Wo J; Zhao M; Liu Z; Dong T; Xiao S
Clin Exp Med; 2022 Feb; 22(1):1-7. PubMed ID: 33990849
[TBL] [Abstract][Full Text] [Related]
11. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
[TBL] [Abstract][Full Text] [Related]
12. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
[TBL] [Abstract][Full Text] [Related]
13. Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence.
Isaksson S; George AM; Jönsson M; Cirenajwis H; Jönsson P; Bendahl PO; Brunnström H; Staaf J; Saal LH; Planck M
Acta Oncol; 2019 Aug; 58(8):1079-1086. PubMed ID: 31230502
[No Abstract] [Full Text] [Related]
14. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA
Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904
[TBL] [Abstract][Full Text] [Related]
15. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
[TBL] [Abstract][Full Text] [Related]
16. Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma.
Melani C; Roschewski M
Oncology (Williston Park); 2016 Aug; 30(8):731-8, 744. PubMed ID: 27539624
[TBL] [Abstract][Full Text] [Related]
17. Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.
Le Goff E; Blanc-Durand P; Roulin L; Lafont C; Loyaux R; MBoumbae DL; Benmaad I; Claudel A; Poullot E; Robe C; Gricourt G; Aissat A; Copie-Bergman C; Lemonnier F; Gaulard P; Itti E; Haioun C; Delfau-Larue MH
Br J Haematol; 2023 Jul; 202(1):54-64. PubMed ID: 37038217
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
Mutter JA; Alig SK; Esfahani MS; Lauer EM; Mitschke J; Kurtz DM; Kühn J; Bleul S; Olsen M; Liu CL; Jin MC; Macaulay CW; Neidert N; Volk T; Eisenblaetter M; Rauer S; Heiland DH; Finke J; Duyster J; Wehrle J; Prinz M; Illerhaus G; Reinacher PC; Schorb E; Diehn M; Alizadeh AA; Scherer F
J Clin Oncol; 2023 Mar; 41(9):1684-1694. PubMed ID: 36542815
[TBL] [Abstract][Full Text] [Related]
19. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R
Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422
[TBL] [Abstract][Full Text] [Related]
20. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]